FDA grants orphan drug status to Kymera blood cancer drug KT-253

Kymera Therapeutics (NASDAQ:KYMR) said that its drug candidate KT-253 has received orphan drug status from the US Food and Drug Administration for the treatment of acute myeloid leukemia.

The company initiated Phase 1 testing of the drug in March for the treatment of various blood cancers. The drug, which targets and degrades the protein MDM2, is intended to help induce cancer cell death.

The orphan drug designation would give the drug seven years of market exclusivity if approved for that indication, according to Kymera.

More on Kymera:

Kymera climbs on data updates for three drug programs (update)

Kymera Therapeutics appoints COO

Kymera upgraded to outperform at Raymond James on improved risk/reward

Kymera off 14% on quarterly results, lack of clarity on trial